Data from part A of the TOT-HER3 trial revealed that HER3-DXd is associated with clinical response, increased immune infiltration, and proliferation suppression with an acceptable safety profile in patients with HR+/HER2-negative early breast cancer, regardless of baseline ERBB3 levels. This evidence concerns the gene ERBB2 and breast carcinoma.